1
|
Alavi N, Rezaei M, Maghami P, Fanipakdel A, Avan A. Nanocarrier System for Increasing the Therapeutic Efficacy of Oxaliplatin. Curr Cancer Drug Targets 2022; 22:361-372. [PMID: 35048809 DOI: 10.2174/1568009622666220120115140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Revised: 11/01/2021] [Accepted: 11/24/2021] [Indexed: 11/22/2022]
Abstract
The application of Oxaliplatin (OxPt) in different malignancies is reported to be accompanied by several side effects including neuropathy, nausea, vomiting, diarrhea, mouth sores, low blood counts, loss of appetite, etc. The passive or active targeting of different tumors can improve OxPt delivery. Considering the demand for novel systems meant to improve the OxPt efficacy and define the shortcomings, we provided an overview of different approaches regarding the delivery of OxPt. There is an extending body of data that exhibits the value of Liposomes and polymer-based drug delivery systems as the most successful systems among the OxPt drug delivery procedures. Several clinical trials have been carried out to investigate the side effects and dose-limiting toxicity of liposomal oxaliplatin such as the assessment on Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors. In addition, several studies indicated the biocompatibility and biodegradability of this product, as well as its option for being fictionalized to derive specialized smart nanosystems for the treatment of cancer. The better delivery of OxPt with weaker side effects could be generated by the exertion of Oxaliplatin, which involves the aggregation of new particles and multifaceted nanocarriers to compose a nanocomposite with both inorganic and organic nanoparticles.
Collapse
Affiliation(s)
- Negin Alavi
- Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | - Majid Rezaei
- Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
- Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Parvaneh Maghami
- Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | - Azar Fanipakdel
- Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Amir Avan
- Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
- Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|
2
|
Wang J, Lun L, Jiang X, Wang Y, Li X, Du G, Wang J. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma. Int Immunopharmacol 2021; 97:107675. [PMID: 33964809 DOI: 10.1016/j.intimp.2021.107675] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Revised: 03/18/2021] [Accepted: 04/11/2021] [Indexed: 02/06/2023]
Abstract
Laryngeal squamous cell carcinoma (LSCC) and hypopharyngeal squamous cell carcinoma (HSCC) seriously affect the life quality of patients. Nowadays, immunotherapy is widely used in the treatment of cancer. Tumor-infiltrating lymphocytes (TILs), programmed cell death 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) play key roles in the immunotherapy of cancer. Moreover, study has reported that the upregulation of PD-L1 and apurinic/apyrimidinic endonuclase 1 (APE1) are associated with tumorigenesis and poor prognosis of gastric cancer. In the present study, the number of CD3+ T lymphocytes and the expressions of PD-1 and PD-L1 in LSCC and HSCC were detected in clinical samples. In addition, the expressions of PD-L1 and APE1 and their correlation were explored. The results showed that PD-1+ T lymphocytes were wildly infiltrated and PD-L1 was overexpressed in LSCC and HSCC tissues. PD-1 had a positive correlation with cancer progression, and glottic and subglottic LSCC tissues might have a more active immune microenvironment. Moreover, the results showed that upregulated co-expression of PD-L1 and APE1 was a biomarker of LSCC, and APE1 could regulate the expression of PD-L1 through NF-κB signaling pathway. In conclusion, the combine detection of the expressions of PD-1, PD-L1 and APE1 will provide predictive value for the treatment of LSCC and HSCC via immune checkpoint inhibitors, which will help us to identify the patient population more likely to benefit from the immune checkpoint inhibitors based on the tumor immune microenvironment.
Collapse
Affiliation(s)
- Juan Wang
- Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao 266061, Shandong, China
| | - Limin Lun
- Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao 266061, Shandong, China
| | - Xin Jiang
- Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China
| | - Yi Wang
- Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao 266061, Shandong, China
| | - Xiaopeng Li
- Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao 266061, Shandong, China
| | - Guoqiang Du
- Department of Otolaryngology Head and Neck Surgery, Qingdao Municipal Hospital (Group), Qingdao 266071, Shandong, China.
| | - Jin Wang
- Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China.
| |
Collapse
|
3
|
Krajewska JB, Bartoszek A, Fichna J. New Trends in Liposome-based Drug Delivery in Colorectal Cancer. Mini Rev Med Chem 2018; 19:3-11. [DOI: 10.2174/1389557518666180903150928] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Revised: 08/23/2018] [Accepted: 08/30/2018] [Indexed: 11/22/2022]
Abstract
Colorectal cancer (CRC) is one of the most common cancers in both men and women. Approximately
one-third of patients do not survive five years from diagnosis, which indicates the need for
treatment improvement, also through new ways of drug delivery. A possible strategy to increase treatment
efficacy is the use of liposomal formulation, which allows delivering both hydrophobic and hydrophilic
compounds with better biocompatibility and reduced side-effects. Liposomal formulations
showed better antitumor activity, longer drug accumulation and no cytotoxic effect on normal cells
when compared to free drugs. In this review, we will present liposomal preparations studied in CRC in
vitro and in vivo. We will focus on the advantages of liposomal delivery over conventional therapy as
well as modifications which increase specificity, drug accumulation and efficacy. Moreover, we will
discuss formulations investigated in clinical trials. Liposomal delivery has a great potential in overcoming
current limitations of cancer therapy and development of this system gives new perspectives in
CRC treatment.
Collapse
Affiliation(s)
- Julia B. Krajewska
- Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Poland
| | - Adrian Bartoszek
- Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Poland
| | - Jakub Fichna
- Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Poland
| |
Collapse
|
4
|
Wang HJ, Li MQ, Liu WW, Hayashi T, Fujisaki H, Hattori S, Tashiro SI, Onodera S, Ikejima T. Collagen gel protects L929 cells from TNFα-induced death by activating NF-κB. Connect Tissue Res 2017; 58:456-463. [PMID: 27764545 DOI: 10.1080/03008207.2016.1248287] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
PURPOSE Type I collagen is one of the most abundant components of extracellular matrix. We previously illustrated that murine fibrosarcoma L929 cells grew well on type I collagen gel and escaped from TNFα-induced cell death. In this study, we investigated the mechanism underlying the protective effect of collagen gel. MATERIAL AND METHODS We used western blot, confocal microscopy, MTT assay and flow cytometry by introducing fluorescence staining to determine the expression levels of nuclear factor kappa B (NF-κB), inhibitory ratio and autophagy. RESULTS L929 cells on collagen gel showed higher expression of NF-κB in the nucleus. Inhibition of NF-κB with pyrrolidine dithiocarbamate hydrochloride (PDTC) or knockdown by NF-κB-siRNA canceled the protective effect of collagen gel on L929 cells from TNFα-induced death, suggesting for the role of NF-κB in the protection from cell death. We found a new aspect of the effect of PDTC on L929 cells cultured on collagen gel. PDTC alone without TNFα induced apoptosis in the L929 cells cultured on collagen gel but not the cells on plastic dish. The apoptosis induction of the L929 cells cultured on collagen gel with PDTC was repressed by inhibiting autophagy with chloroquine, an autophagy inhibitor, suggesting that autophagy contributes to the death induced by the treatment with PDTC. Possible underlying mechanism of this finding is discussed. CONCLUSION NF-κB played an important role in protecting the L929 cells cultured on collagen gel from TNFα-induced death.
Collapse
Affiliation(s)
- Hong-Ju Wang
- a China-Japan Research Institute of Medical and Pharmaceutical Sciences , Shenyang Pharmaceutical University , Shenyang , China
| | - Meng-Qi Li
- a China-Japan Research Institute of Medical and Pharmaceutical Sciences , Shenyang Pharmaceutical University , Shenyang , China
| | - Wei-Wei Liu
- a China-Japan Research Institute of Medical and Pharmaceutical Sciences , Shenyang Pharmaceutical University , Shenyang , China
| | - Toshihiko Hayashi
- a China-Japan Research Institute of Medical and Pharmaceutical Sciences , Shenyang Pharmaceutical University , Shenyang , China
| | - Hitomi Fujisaki
- b Nippi Research Institute of Biomatrix, Nippi, Incorporated , Toride , Japan
| | - Shunji Hattori
- b Nippi Research Institute of Biomatrix, Nippi, Incorporated , Toride , Japan
| | - Shin-Ichi Tashiro
- c Department of Medical Education & Primary Care , Kyoto Prefectural University of Medicine , Kyoto , Japan
| | - Satoshi Onodera
- d Department of Clinical and Pharmaceutical Sciences , Showa Pharmaceutical University , Tokyo , Japan
| | - Takashi Ikejima
- a China-Japan Research Institute of Medical and Pharmaceutical Sciences , Shenyang Pharmaceutical University , Shenyang , China
| |
Collapse
|
5
|
Revisiting the use of sPLA 2 -sensitive liposomes in cancer therapy. J Control Release 2017; 261:163-173. [DOI: 10.1016/j.jconrel.2017.06.024] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2017] [Revised: 06/21/2017] [Accepted: 06/24/2017] [Indexed: 11/24/2022]
|
6
|
Ur Rehman SS, Lim K, Wang-Gillam A. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer. Expert Rev Anticancer Ther 2016; 16:485-92. [PMID: 27043737 DOI: 10.1080/14737140.2016.1174581] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease with half of patients diagnosed in the metastatic setting. Until recently, patients after progression on front-line gemcitabine-based regimen had no standard second-line option, although flouropyrimidine-based regimens were frequently used in this setting. Encapsulation of chemotherapeutics in liposomal formulation is an effective way of prolonging drug deposition thereby enhancing cytotoxic efficacy. In a large phase III randomized trial on metastatic PDAC patients who progressed after gemcitabine-based chemotherapy, a novel nanoliposome-encapsulated irinotecan (PEP02, MM-398, nal-IRI, Onivyde, Merrimack, Boston, US) plus fluorouracil and folinic acid demonstrated a significant survival advantage compared to fluorouracil and folinic acid alone. This pivotal study led to the recent FDA approval of nanoliposomal irinotecan in patients with metastatic PDAC. In this article, we will review the literature regarding existing treatment options for metastatic PDAC, focusing specifically on nanoliposomal irinotecan in the clinical setting and its future implication.
Collapse
Affiliation(s)
- Sana Saif Ur Rehman
- a Division of Oncology, Department of Medicine , Washington University in St. Louis , St. Louis , MO , USA
| | - Kian Lim
- a Division of Oncology, Department of Medicine , Washington University in St. Louis , St. Louis , MO , USA.,b Siteman Cancer Center , Washington University School of Medicine , St. Louis , MO , USA
| | - Andrea Wang-Gillam
- a Division of Oncology, Department of Medicine , Washington University in St. Louis , St. Louis , MO , USA.,b Siteman Cancer Center , Washington University School of Medicine , St. Louis , MO , USA
| |
Collapse
|
7
|
Gharib A, Faezizadeh Z, Mesbah-Namin SAR, Saravani R. Experimental treatment of breast cancer-bearing BALB/c mice by artemisinin and transferrin-loaded magnetic nanoliposomes. Pharmacogn Mag 2015; 11:S117-22. [PMID: 26109756 PMCID: PMC4461950 DOI: 10.4103/0973-1296.157710] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2014] [Revised: 12/27/2014] [Accepted: 05/27/2015] [Indexed: 11/20/2022] Open
Abstract
Background: The combination of artemisinin and transferrin exhibits versatile anticancer activities. In previous, we successfully prepared artemisinin and transferrin-loaded magnetic nanoliposomes and evaluated their anti-proliferative activity against MCF-7 and MDA-MB-231 cell lines in vitro. In this study, we investigate the in vivo anti-breast cancer activity of artemisinin and transferrin-loaded magnetic nanoliposome against breast transplanted tumors in BALB/c mice model. Materials and Methods: Artemisinin and transferrin-loaded magnetic nanoliposomes were prepared and characterized for some physiochemical properties. Pieces of tumor tissue from the breast cancer-bearing BALB/c mice were transplanted subcutaneously to the syngeneic female BALB/c mice. In the presence of the external magnet that placed at the breast tumor site, the tissue distribution and tumor-suppressing effects of prepared nanoliposomes on tumor growth was evaluated. Results: The prepared nanoliposomes have fine spherical shape, rough surface, nano-sized diameter and magnetic properties. At 2 h after treatment, the intravenous administration of artemisinin and transferrin-loaded magnetic nanoliposomes followed using the magnetic field approximately produced 10- and 5.5-fold higher levels of artemisinin and transferrin in the tumors, respectively, compared with free artemisinin and transferrin. Moreover, in the presence of an external magnetic field, the prepared nanoliposomes could significantly induce apoptosis in the mice breast cancer cells as well as could reduce tumor volume in tumorized mice at 15 days after treatment. Conclusion: The data suggested that the artemisinin and transferrin-loaded magnetic nanoliposomes would be a good choice for the breast tumor-targeted therapy, due to its high targeting efficiency.
Collapse
Affiliation(s)
- Amir Gharib
- Department of Laboratory Sciences, Borujerd Branch, Islamic Azad University, Borujerd, Iran
| | - Zohreh Faezizadeh
- Department of Laboratory Sciences, Borujerd Branch, Islamic Azad University, Borujerd, Iran
| | | | - Ramin Saravani
- Department of Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
| |
Collapse
|